The O O O O
New O O O O
Era O O O O
of O O O O
Virus-Like O O O O
Particles O O O O
Based O O O O
Vaccines O O O O
Mona O O O O
Mohsen* O O O O
The O O O O
Jenner O O O O
Institute, O O O O
Nuffield O O ScientificAuthority O
Department O O ScientificAuthority O
of O O ScientificAuthority O
Medicine, O O ScientificAuthority O
University O O ScientificAuthority O
of O O ScientificAuthority O
Oxford, O O ScientificAuthority O
Qatar O O O O
*Corresponding O O O O
author: O O O O
Mona O O O O
Mohsen, O O O O
The O O O O
Jenner O O O O
Institute, O O O O
Nuffield O O O O
Department O O O O
of O O O O
of O O O O
Mar O O O O
05, O O O O
Copyright: O O O O
Â© O O O O
2016 O O O O
Mohsen O O O O
M. O O O O
This O O O O
is O O O O
an O O O O
open-access O O O O
article O O O O
distributed O O O O
under O O O O
the O O O O
terms O O O O
of O O O O
the O O O O
Creative O O O O
Commons O O O O
Attribution O O O O
License, O O O O
which O O O O
permits O O O O
unrestricted O O O O
use, O O O O
distribution, O O O O
and O O O O
reproduction O O O O
in O O O O
any O O O O
medium, O O O O
provided O O O O
the O O O O
original O O O O
author O O O O
and O O O O
source O O O O
are O O O O
credited. O O O O
Opinion Reason 4 O O
V Reason 4 O O
irus-like Reason 4 O O
particles Reason 4 O O
or Reason 4 O O
what Reason 4 O O
is Reason 4 O O
called Reason 4 O O
VLPs Reason 4 O O
for Reason 4 O O
short Reason 4 O O
are Reason 4 O O
considered Reason 4 O O
a Reason 4 O O
useful Reason 4 O O
tool Reason 4 O O
in Reason 4 O O
the Reason 4 O O
development Reason 4 O O
of Reason 4 O O
vaccines. Reason 4 O O
These Reason 4 O O
VLPs-based Reason 4 O O
vaccines Reason 4 O O
h Reason 4 O O
ave Reason 4 O O
attracted Reason 4 O O
the Reason 4 O O
attention Reason 4 O O
of Reason 4 O O
many Reason 4 O O
biotech Reason 4 O O
and Reason 4 O O
pharmaceutical Reason 4 O O
companies Reason 4 O O
as Reason 4 O O
effective Reason 4 O O
treatment Reason 4 O O
for Reason 4 O O
many Reason 4 O O
types Reason 4 O O
of Reason 4 O O
non-infectious Reason 4 O O
c Reason 4 O O
hronic Reason 4 O O
diseases. Reason 4 O O
VLPs Reason 4 O O
simply Reason 4 O O
resemble Reason 4 O O
viruses; Reason 4 O O
however Reason 4 O O
they Reason 4 O O
are Reason 4 O O
non- Reason 4 O O
infectious Reason 4 O O
due Reason 4 O O
to Reason 4 O O
the Reason 4 O O
lack Reason 4 O O
of Reason 4 O O
viral Reason 4 O O
genome. Reason 4 O O
The O O O O
expression O O O O
of O O O O
envelop O O O O
or O O O O
c O O O O
apsid O O O O
proteins O O O O
result O O O O
in O O O O
the O O O O
self-assembly O O O O
of O O O O
the O O O O
particle, O O O O
this O O O O
assembly O O O O
can O O O O
easily O O O O
be O O O O
carried O O O O
out O O O O
in O O O O
bacteria, O O O O
yeast, O O O O
plant O O O O
cells O O O O
or O O O O
insect O O O O
cell O O O O
lines. O O O O
The O O O O
presence O O O O
of O O O O
repetitive O O O O
viral O O O O
surface O O O O
protein O O O O
epitopes O O O O
is O O O O
s O O O O
uccessful O O O O
in O O O O
eliciting O O O O
strong O O O O
B O O O O
cell O O O O
responses. O O O O
VLPs O O O O
have O O O O
also O O O O
high O O O O
safety O O O O
profile O O O O
due O O O O
to O O O O
the O O O O
lack O O O O
of O O O O
viral O O O O
genome O O O O
and O O O O
lack O O O O
of O O O O
the O O O O
ability O O O O
to O O O O
r O O O O
eplicate. O O O O
This O O O O
area O O O O
of O O O O
research O O O O
is O O O O
not O O O O
really O O O O
new, O O O O
the O O O O
discovery O O O O
of O O O O
h O O O O
epatitis O O O O
B O O O O
virus O O O O
derived O O O O
VLPs O O O O
goes O O O O
back O O O O
to O O O O
1976. O O O O
An O O O O
interesting O O O O
class O O O O
of O O O O
VLPs O O O O
is O O O O
the O O O O
"bacteriophage O O O O
Q" O O O O
, O O O O
an O O O O
icosahedral O O O O
virus O O O O
with O O O O
a O O O O
diameter O O O O
of O O O O
about O O O O
30nm. O O O O
This O O O O
virus O O O O
can O O O O
r O O O O
eplicate O O O O
efficiently O O O O
in O O O O
E.coli O O O O
. O O O O
The O O O O
capsid O O O O
protein, O O O O
which O O O O
is O O O O
~ O O O O
14kDa, O O O O
can O O O O
b O O O O
e O O O O
re-combinantly O O O O
expressed O O O O
in O O O O
E.coli O O O O
and O O O O
spontaneously O O O O
assembles O O O O
in O O O O
the O O O O
cytoplasmic O O O O
compartment O O O O
of O O O O
the O O O O
bacteria. O O O O
The O O O O
VLPs O O O O
are O O O O
then O O O O
ready O O O O
f O O O O
or O O O O
the O O O O
purification O O O O
process O O O O
using O O O O
the O O O O
modern O O O O
biotechnology O O O O
t O O O O
echniques. O O O O
The Reason 4 O O
VLPs Reason 4 O O
themselves Reason 4 O O
are Reason 4 O O
not Reason 4 O O
the Reason 4 O O
target Reason 4 O O
of Reason 4 O O
the Reason 4 O O
vaccine Reason 4 O O
but Reason 4 O O
rat Reason 4 O O
her Reason 4 O O
a Reason 4 O O
template Reason 4 O O
to Reason 4 O O
display Reason 4 O O
different Reason 4 O O
antigens Reason 4 O O
of Reason 4 O O
interest. Reason 4 O O
The Reason 4 O O
idea Reason 4 O O
is Reason 4 O O
to Reason 4 O O
im Reason 4 O O
prove Reason 4 O O
the Reason 4 O O
immunogenicity Reason 4 O O
of Reason 4 O O
conjugated Reason 4 O O
antigens Reason 4 O O
(the Reason 4 O O
targets Reason 4 O O
of Reason 4 O O
the Reason 4 O O
vaccine) Reason 4 O O
to Reason 4 O O
enhance Reason 4 O O
B Reason 4 O O
cell Reason 4 O O
receptor Reason 4 O O
cross-linking Reason 4 O O
and Reason 4 O O
uptake Reason 4 O O
by Reason 4 O O
dendritic Reason 4 O O
cells Reason 4 O O
resulting Reason 4 O O
in Reason 4 O O
efficient Reason 4 O O
presentation Reason 4 O O
to Reason 4 O O
the Reason 4 O O
adaptive Reason 4 O O
imm Reason 4 O O
unocytes, Reason 4 O O
an Reason 4 O O
efficient Reason 4 O O
active Reason 4 O O
immunisation Reason 4 O O
strategy. Reason 4 O O
A O O O O
ctive O O O O
immunization O O O O
using O O O O
VLPs O O O O
has O O O O
several O O O O
advantages O O O O
over O O O O
the O O O O
passive O O O O
method O O O O
where O O O O
monoclonal O O O O
antibodies O O O O
are O O O O
used. O O O O
mAbs O O O O
have O O O O
already O O O O
shown O O O O
significant O O O O
results O O O O
in O O O O
the O O O O
research O O O O
and O O O O
clinical O O O O
settings O O O O
s O O O O
uch O O O O
as O O O O
in O O O O
the O O O O
case O O O O
of O O O O
arthritis O O O O
or O O O O
other O O O O
chronic O O O O
diseases. O O O O
However, O O O O
mAbs O O O O
suffer O O O O
from O O O O
several O O O O
drawbacks, O O O O
such O O O O
as O O O O
primary O O O O
and O O O O
secondary O O O O
t O O O O
reatment O O O O
failure, O O O O
the O O O O
undesirable O O O O
cost O O O O
production O O O O
specially O O O O
for O O O O
long O O O O
term O O O O
treatment O O O O
in O O O O
chronic O O O O
diseases O O O O
and O O O O
tolerability O O O O
issues. O O O O
The O O O O
following O O O O
paragraphs O O O O
summarize O O O O
some O O O O
interesting O O O O
work O O O O
carried O O O O
o O O O O
ut O O O O
in O O O O
this O O O O
field O O O O
by O O O O
the O O O O
pioneer O O O O
in O O O O
VLPs-Based O O O O
Vaccines O O O O
(Martin O O O O
B O O O O
achmann); O O O O
the O O O O
professor O O O O
of O O O O
vaccinology O O O O
at O O O O
the O O O O
University O O ScientificAuthority O
of O O ScientificAuthority O
Oxfordand O O ScientificAuthority O
the O O O O
professor O O O O
of O O O O
Immunology O O O O
at O O O O
the O O O O
University O O ScientificAuthority O
of O O ScientificAuthority O
Bern. O O ScientificAuthority O
A Reason 5 O O
VLP- Reason 5 O O
b Reason 5 O O
ased Reason 5 O O
vaccine Reason 5 O O
for Reason 5 O O
hypertension Reason 5 O O
has Reason 5 O O
shown Reason 5 O O
promising Reason 5 O O
results Reason 5 O O
in Reason 5 O O
the Reason 5 O O
preclinical Reason 5 O O
studies Reason 5 O O
and Reason 5 O O
reached Reason 5 O O
phase Reason 5 O O
II Reason 5 O O
clinical Reason 5 O O
trial Reason 5 O O
with Reason 5 O O
good Reason 5 O O
safety Reason 5 O O
and Reason 5 O O
efficacy Reason 5 O O
profile. Reason 5 O O
Simply O O O O
Angiotensin-II O O O O
peptide O O O O
was O O O O
efficiently O O O O
conjugated O O O O
to O O O O
VLPs O O O O
(Q) O O O O
which O O O O
was O O O O
highly O O O O
immunogenic O O O O
in O O O O
different O O O O
animal O O O O
models O O O O
as O O O O
well O O O O
as O O O O
humans. O O O O
The O O O O
results O O O O
obtained O O O O
in O O O O
the O O O O
phase O O O O
II O O O O
s O O O O
tudy O O O O
indicated O O O O
that O O O O
(AngQ) O O O O
can O O O O
reduce O O O O
the O O O O
blood O O O O
pressure O O O O
to O O O O
the O O O O
same O O O O
levels O O O O
obtained O O O O
by O O O O
ACE O O O O
blockers. O O O O
This Reason 5 O O
vaccine Reason 5 O O
is Reason 5 O O
favourable Reason 5 O O
over Reason 5 O O
t Reason 5 O O
he Reason 5 O O
conventional Reason 5 O O
treatment Reason 5 O O
as Reason 5 O O
it Reason 5 O O
induces Reason 5 O O
long Reason 5 O O
lasting Reason 5 O O
effect Reason 5 O O
with Reason 5 O O
less Reason 5 O O
n Reason 5 O O
umber Reason 5 O O
of Reason 5 O O
doses. Reason 5 O O
Also Reason 5 O O
this Reason 5 O O
may Reason 5 O O
overcome Reason 5 O O
the Reason 5 O O
problem Reason 5 O O
of Reason 5 O O
inconsistency Reason 5 O O
happened Reason 5 O O
with Reason 5 O O
daily Reason 5 O O
tablets. Reason 5 O O
VLPs Reason 5 O O
have Reason 5 O O
also Reason 5 O O
been Reason 5 O O
tested Reason 5 O O
as Reason 5 O O
an Reason 5 O O
effective Reason 5 O O
vaccine Reason 5 O O
in Reason 5 O O
allergy Reason 5 O O
r Reason 5 O O
epresenting Reason 5 O O
a Reason 5 O O
major Reason 5 O O
problem Reason 5 O O
worldwide. Reason 5 O O
Q O O O O
particles O O O O
were O O O O
filled O O O O
up O O O O
w O O O O
ith O O O O
DNA-oligonucleotides O O O O
containing O O O O
CpG-motifs O O O O
which O O O O
is O O O O
known O O O O
to O O O O
stimulate O O O O
toll O O O O
receptor O O O O
9 O O O O
of O O O O
the O O O O
innate O O O O
immune O O O O
system. O O O O
The O O O O
authors O O O O
h O O O O
ave O O O O
focused O O O O
on O O O O
allergic O O O O
rhinitis O O O O
and O O O O
asthma O O O O
and O O O O
they O O O O
concluded O O O O
that O O O O
clinically O O O O
effective O O O O
treatment O O O O
can O O O O
be O O O O
obtained O O O O
even O O O O
in O O O O
the O O O O
absence O O O O
of O O O O
al O O O O
lergens. O O O O
Results O O O O
encourage O O O O
further O O O O
investigation O O O O
of O O O O
virus-like O O O O
particles O O O O
and O O O O
CpG-motifs O O O O
in O O O O
immunotherapy, O O O O
either O O O O
as O O O O
a O O O O
stand-alone O O O O
product, O O O O
or O O O O
as O O O O
adjuvants O O O O
for O O O O
allergen-specific O O O O
immunotherapy. O O O O
VLP Reason 5 O O
s Reason 5 O O
have Reason 5 O O
also Reason 5 O O
shown Reason 5 O O
promising Reason 5 O O
results Reason 5 O O
with Reason 5 O O
cancer; Reason 5 O O
a Reason 5 O O
melanoma Reason 5 O O
specific Reason 5 O O
peptide Reason 5 O O
was Reason 5 O O
chemically Reason 5 O O
linked Reason 5 O O
to Reason 5 O O
Q Reason 5 O O
particles Reason 5 O O
which Reason 5 O O
also Reason 5 O O
have Reason 5 O O
been Reason 5 O O
loaded Reason 5 O O
with Reason 5 O O
DNA Reason 5 O O
oligonucleotides Reason 5 O O
containing Reason 5 O O
CpGs Reason 5 O O
motifs. Reason 5 O O
In Reason 5 O O
this Reason 5 O O
study Reason 5 O O
they Reason 5 O O
have Reason 5 O O
used Reason 5 O O
Melan-A/Mart-1 Reason 5 O O
peptide Reason 5 O O
as Reason 5 O O
a Reason 5 O O
potent Reason 5 O O
inducer Reason 5 O O
of Reason 5 O O
specific Reason 5 O O
cytotoxic Reason 5 O O
T-cells Reason 5 O O
responses. Reason 5 O O
The Reason 5 O O
vaccine Reason 5 O O
was Reason 5 O O
tested Reason 5 O O
in Reason 5 O O
phase Reason 5 O O
I/II Reason 5 O O
clinical Reason 5 O O
trials Reason 5 O O
with Reason 5 O O
melanoma Reason 5 O O
patients Reason 5 O O
in Reason 5 O O
stages Reason 5 O O
II-IV Reason 5 O O
. Reason 5 O O
The Reason 5 O O
vaccine Reason 5 O O
was Reason 5 O O
very Reason 5 O O
well Reason 5 O O
tolerated Reason 5 O O
in Reason 5 O O
these Reason 5 O O
patients Reason 5 O O
and Reason 5 O O
a Reason 5 O O
good Reason 5 O O
percentage Reason 5 O O
showed Reason 5 O O
detectable Reason 5 O O
specific Reason 5 O O
T-cell Reason 5 O O
response Reason 5 O O
to Reason 5 O O
the Reason 5 O O
above Reason 5 O O
mentioned Reason 5 O O
antigen Reason 5 O O
with Reason 5 O O
significant Reason 5 O O
levels Reason 5 O O
of Reason 5 O O
INFg Reason 5 O O
as Reason 5 O O
well. Reason 5 O O
The Reason 5 O O
research Reason 5 O O
concluded Reason 5 O O
that Reason 5 O O
vaccin Reason 5 O O
ation Reason 5 O O
with Reason 5 O O
CpGs Reason 5 O O
loaded Reason 5 O O
virus-like Reason 5 O O
nanoparticles Reason 5 O O
is Reason 5 O O
associated Reason 5 O O
with Reason 5 O O
a Reason 5 O O
human Reason 5 O O
CD8 Reason 5 O O
T-cell Reason 5 O O
response Reason 5 O O
with Reason 5 O O
properties Reason 5 O O
of Reason 5 O O
a Reason 5 O O
potential Reason 5 O O
long- Reason 5 O O
term Reason 5 O O
immune Reason 5 O O
protection Reason 5 O O
from Reason 5 O O
the Reason 5 O O
disease. Reason 5 O O
In Reason 5 O O
conclusion, Reason 5 O O
VLPs-Based Reason 5 O O
Vaccines Reason 5 O O
constitute Reason 5 O O
a Reason 5 O O
promising Reason 5 O O
field Reason 5 O O
for Reason 5 O O
t Reason 5 O O
reating Reason 5 O O
different Reason 5 O O
non-infectious Reason 5 O O
chronic Reason 5 O O
diseases Reason 5 O O
with Reason 5 O O
affordable Reason 5 O O
expenses, Reason 5 O O
high Reason 5 O O
efficacy Reason 5 O O
and Reason 5 O O
large Reason 5 O O
safety Reason 5 O O
profiles.Mohsen, Reason 5 O O
Gene O O O O
Technol O O O O
2016, O O O O
5:1 O O O O
DOI: O O O O
10.4172/2329-6682.1000136 O O O O
Opinion O O O O
Open O O O O
Technol O O O O
ISS O O O O
N:2329-6682 O O O O
open O O O O
access O O O O
JournalVolume O O O O
5 O O O O
Issue O O O O
1 O O O O
1000.136GeneTechnology O O O O
ISSN: O O O O
2329-6682Gene O O O O
Technology O O O O
